|
1
|
Crocetto F, Calogero A, Santangelo M, Fernicola A, Varlese F, Mirto BF, Machiella F, Falcone A, Pagano G, Dinacci F, Giampaglia G, Varriale D, Trama F, Iaconis S, Del Giudice F, Busetto GM, Ferro M, Lasorsa F, Lucarelli G, Imbimbo C, Barone B. The Role of Butirprost ® as an Adjuvant in Enhancing the Effect of Antibiotics in Patients Affected by Chronic Bacterial Prostatitis: A Randomized Prospective Trial. MEDICINA (KAUNAS, LITHUANIA) 2025; 61:148. [PMID: 39859130 PMCID: PMC11767095 DOI: 10.3390/medicina61010148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/25/2024] [Revised: 12/22/2024] [Accepted: 01/15/2025] [Indexed: 01/27/2025]
Abstract
Bacterial prostatitis (BP) is a common prostatic infection characterized by pain and urinary symptoms, often with negative bacterial cultures from prostatic secretions. It affects young and older men bimodally and impacts quality of life (QoL) significantly. Background and Objectives: Treatment typically involves antibiotics, but a multimodal approach with additional nutraceuticals may enhance outcomes. This study aimed to assess the efficacy of Butirprost® in association with fluoroquinolones in patients with chronic bacterial prostatitis (CBP). Materials and Methods: Patients diagnosed with prostatitis (positive Meares-Stamey test and symptom duration > 3 months) at the University of Naples "Federico II", Italy, from March 2024 to July 2024 were included in this study. All patients underwent bacterial cultures. Patients were randomized into two groups: Group A received antibiotics plus Butirprost® (sodium hyaluronate plus Plantago major) for one month, while Group B received antibiotics alone. International Prostatic Symptoms Score (IPSS) and National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) questionnaires were administered at baseline and at 15 and 30 days. Results: Out of 60 patients (Group A: 30, Group B: 30), Group A showed significant improvement in IPSS and NIH-CPSI scores at 15 and 30 days compared to Group B. Notable improvements were observed in pain, urinary symptoms, and QoL. Conclusions: The administration of Butirprost® along with fluoroquinolones resulted in a significant improvement in pain, urinary symptoms, and quality of life along with improvements in both IPSS and NIH-CPSI scores, in patients affected by chronic bacterial prostatitis compared with fluoroquinolones alone.
Collapse
Affiliation(s)
- Felice Crocetto
- Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy; (F.C.); (B.F.M.); (F.M.); (A.F.); (G.P.); (F.D.); (G.G.); (D.V.); (S.I.); (C.I.)
| | - Armando Calogero
- Section of General Surgery, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80131 Naples, Italy; (A.C.); (M.S.); (A.F.); (F.V.)
| | - Michele Santangelo
- Section of General Surgery, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80131 Naples, Italy; (A.C.); (M.S.); (A.F.); (F.V.)
| | - Agostino Fernicola
- Section of General Surgery, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80131 Naples, Italy; (A.C.); (M.S.); (A.F.); (F.V.)
| | - Filippo Varlese
- Section of General Surgery, Department of Advanced Biomedical Sciences, University of Naples Federico II, 80131 Naples, Italy; (A.C.); (M.S.); (A.F.); (F.V.)
| | - Benito Fabio Mirto
- Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy; (F.C.); (B.F.M.); (F.M.); (A.F.); (G.P.); (F.D.); (G.G.); (D.V.); (S.I.); (C.I.)
| | - Fabio Machiella
- Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy; (F.C.); (B.F.M.); (F.M.); (A.F.); (G.P.); (F.D.); (G.G.); (D.V.); (S.I.); (C.I.)
| | - Alfonso Falcone
- Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy; (F.C.); (B.F.M.); (F.M.); (A.F.); (G.P.); (F.D.); (G.G.); (D.V.); (S.I.); (C.I.)
| | - Giovanni Pagano
- Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy; (F.C.); (B.F.M.); (F.M.); (A.F.); (G.P.); (F.D.); (G.G.); (D.V.); (S.I.); (C.I.)
| | - Fabrizio Dinacci
- Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy; (F.C.); (B.F.M.); (F.M.); (A.F.); (G.P.); (F.D.); (G.G.); (D.V.); (S.I.); (C.I.)
| | - Gaetano Giampaglia
- Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy; (F.C.); (B.F.M.); (F.M.); (A.F.); (G.P.); (F.D.); (G.G.); (D.V.); (S.I.); (C.I.)
| | - Domenico Varriale
- Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy; (F.C.); (B.F.M.); (F.M.); (A.F.); (G.P.); (F.D.); (G.G.); (D.V.); (S.I.); (C.I.)
| | - Francesco Trama
- Urology Complex Unit, ASL Napoli 2 Nord ‘Santa Maria delle Grazie’ Hospital, 80078 Pozzuoli, Italy;
| | - Salvatore Iaconis
- Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy; (F.C.); (B.F.M.); (F.M.); (A.F.); (G.P.); (F.D.); (G.G.); (D.V.); (S.I.); (C.I.)
| | - Francesco Del Giudice
- Department of Urology, Policlinico Umberto I, Sapienza University of Rome, 00185 Rome, Italy;
| | - Gian Maria Busetto
- Department of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy; (G.M.B.); (F.L.)
| | - Matteo Ferro
- Division of Urology, European Institute of Oncology (IEO) IRCCS, 20139 Milan, Italy;
| | - Francesco Lasorsa
- Department of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy; (G.M.B.); (F.L.)
| | - Giuseppe Lucarelli
- Urology, Andrology and Kidney Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area-Urology, University of Bari “Aldo Moro”, 70121 Bari, Italy;
| | - Ciro Imbimbo
- Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy; (F.C.); (B.F.M.); (F.M.); (A.F.); (G.P.); (F.D.); (G.G.); (D.V.); (S.I.); (C.I.)
| | - Biagio Barone
- Department of Urology, 196152 Ospedale San Paolo, ASL NA1 Centro Naples, 80145 Naples, Italy
| |
Collapse
|
|
2
|
Wang Y, Lao Y, Li R, You C, Qing L, Xiao X, Liu S, Wang W, Zhao Y, Dong Z. Network pharmacological analysis and experimental study of melatonin in chronic prostatitis/chronic pelvic pain syndrome. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2024; 397:8691-8706. [PMID: 38822120 DOI: 10.1007/s00210-024-03183-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2023] [Accepted: 05/22/2024] [Indexed: 06/02/2024]
Abstract
This study is aimed at exploring the potential mechanisms of melatonin (MT) in treating chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) using network pharmacology and experimental study. The target genes of MT were acquired from the Swiss Target Prediction, SuperPred, SEA, and PharmMapper databases, and the CP/CPPS targets were collected based on OMIM, DisGeNET, and GeneCards databases. The intersection of MT and CP/CPPS target genes was analyzed. A PPI network was constructed using Cytoscape to identify core targets. The shared targets underwent GO and KEGG enrichment analyses by Using R software. Molecular docking of MT with core targets was performed using AutoDock and PyMOL. GROMACS software was used for molecular dynamics simulation. And using cell experiments to verify the potential effect of MT in CP/CPPS. Network pharmacology analysis reveals 284 shared targets between MT and CP/CPPS, with AKT1, SRC, HSP90AA1, PTGS2, BCL2L1, ALB, CASP3, NFKB1, HIF1A, and ESR1 identified as key targets. Enrichment analysis indicates that MT affects CP/CPPS through various biological processes, and pathway analysis emphasizes the significance of PI3K-Akt, MAPK, Ras, FoxO, HIF-1, EGFR, and apoptosis pathways. Molecular docking confirms strong binding between MT and core targets. It is worth noting that the molecular dynamics simulation showed that the average binding free energy of AKT1, PTGS2, ALB, HSP90AA1 proteins, and MT was - 26.15, - 29.48, - 18.59, and - 20.09 kcal/mol, respectively. These results indicated that AKT1, PTGS2, ALB, and HSP90AA1 proteins were strongly bound to MT. Cell experiments demonstrate that MT can inhibit the secretion of IL-1β, IL-6, and TNF-α in LPS-induced RWPE-1 cells, alleviate inflammation, and suppress cell apoptosis and oxidative stress. Network pharmacology, molecular docking, molecular dynamics simulation, and cell experiments showed that MT could play a role in CP/CPPS by regulating multiple targets and pathways. These findings provide an important scientific basis for further exploration of the molecular mechanism and clinical application of MT in CP/CPPS treatment and are expected to provide new ideas and directions for the development of novel therapeutic strategies.
Collapse
Affiliation(s)
- Yanan Wang
- Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China
- Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China
- Gansu Province Key Laboratory of Urological Diseases, Lanzhou, 730030, Gansu, China
| | - Yongfeng Lao
- Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China
- Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China
- Gansu Province Key Laboratory of Urological Diseases, Lanzhou, 730030, Gansu, China
| | - Rongxin Li
- Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China
- Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China
- Gansu Province Key Laboratory of Urological Diseases, Lanzhou, 730030, Gansu, China
| | - Chengyu You
- Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China
- Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China
- Gansu Province Key Laboratory of Urological Diseases, Lanzhou, 730030, Gansu, China
| | - Liangliang Qing
- Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China
- Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China
- Gansu Province Key Laboratory of Urological Diseases, Lanzhou, 730030, Gansu, China
| | - Xi Xiao
- Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China
- Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China
- Gansu Province Key Laboratory of Urological Diseases, Lanzhou, 730030, Gansu, China
| | - Shuai Liu
- Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China
- Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China
- Gansu Province Key Laboratory of Urological Diseases, Lanzhou, 730030, Gansu, China
| | - Wenyun Wang
- Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China
- Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China
- Gansu Province Key Laboratory of Urological Diseases, Lanzhou, 730030, Gansu, China
| | - Yu Zhao
- Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China
- Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China
- Gansu Province Key Laboratory of Urological Diseases, Lanzhou, 730030, Gansu, China
| | - Zhilong Dong
- Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China.
- Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730030, Gansu, China.
- Gansu Province Key Laboratory of Urological Diseases, Lanzhou, 730030, Gansu, China.
| |
Collapse
|
|
3
|
Wu WL, Bamodu OA, Wang YH, Hu SW, Tzou KY, Yeh CT, Wu CC. Extracorporeal Shockwave Therapy (ESWT) Alleviates Pain, Enhances Erectile Function and Improves Quality of Life in Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. J Clin Med 2021; 10:3602. [PMID: 34441902 PMCID: PMC8396816 DOI: 10.3390/jcm10163602] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Revised: 08/03/2021] [Accepted: 08/10/2021] [Indexed: 12/11/2022] Open
Abstract
PURPOSE Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), affecting over 90% of patients with symptomatic prostatitis, remains a therapeutic challenge and adversely affects patients' quality of life (QoL). This study probed for likely beneficial effects of ESWT, evaluating its extent and durability. PATIENTS AND METHODS Standardized indices, namely the pain, urinary, and QoL domains and total score of NIH-CPSI, IIEF-5, EHS, IPSS, and AUA QoL_US were employed in this study of patients with CP/CPPS who had been refractory to other prior treatments (n = 215; age range: 32-82 years; median age: 57.5 ± 12.4 years; modal age: 41 years). RESULTS For CP symptoms, the mean pre-ESWT NIH-CPSI total score of 27.1 ± 6.8 decreased by 31.3-53.6% over 12 months after ESWT. The mean pre-ESWT NIH-CPSI pain (12.5 ± 3.3), urinary (4.98 ± 2.7), and QoL (9.62 ± 2.1) domain scores improved by 2.3-fold, 2.2-fold, and 2.0-fold, respectively, by month 12 post-ESWT. Compared with the baseline IPSS of 13.9 ± 8.41, we recorded 27.1-50.9% amelioration of urinary symptoms during the 12 months post-ESWT. For erectile function, compared to pre-ESWT values, the IIEF-5 also improved by ~1.3-fold by month 12 after ESWT. This was corroborated by EHS of 3.11 ± 0.99, 3.37 ± 0.65, 3.42 ± 0.58, 3.75 ± 0.45, and 3.32 ± 0.85 at baseline, 1, 2, 6, and 12 months post-ESWT. Compared to the mean pre-ESWT QoL score (4.29 ± 1.54), the mean QoL values were 3.26 ± 1.93, 3.45 ± 2.34, 3.25 ± 1.69, and 2.6 ± 1.56 for months 1, 2, 6, and 12 after ESWT, respectively. CONCLUSIONS This study shows ESWT, an outpatient and easy-to-perform, minimally invasive procedure, effectively alleviates pain, improves erectile function, and ameliorates quality of life in patients with refractory CP/CPPS.
Collapse
Affiliation(s)
- Wen-Ling Wu
- Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan; (W.-L.W.); (O.A.B.); (S.-W.H.); (K.-Y.T.)
- TMU Research Center of Urology and Kidney (TMU-RCUK), Taipei Medical University, Taipei City 110, Taiwan
| | - Oluwaseun Adebayo Bamodu
- Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan; (W.-L.W.); (O.A.B.); (S.-W.H.); (K.-Y.T.)
- Department of Hematology and Oncology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan
- Department of Medical Research, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan; (Y.-H.W.); (C.-T.Y.)
| | - Yuan-Hung Wang
- Department of Medical Research, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan; (Y.-H.W.); (C.-T.Y.)
- Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
| | - Su-Wei Hu
- Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan; (W.-L.W.); (O.A.B.); (S.-W.H.); (K.-Y.T.)
- TMU Research Center of Urology and Kidney (TMU-RCUK), Taipei Medical University, Taipei City 110, Taiwan
- Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
| | - Kai-Yi Tzou
- Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan; (W.-L.W.); (O.A.B.); (S.-W.H.); (K.-Y.T.)
- TMU Research Center of Urology and Kidney (TMU-RCUK), Taipei Medical University, Taipei City 110, Taiwan
- Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 110, Taiwan
| | - Chi-Tai Yeh
- Department of Medical Research, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan; (Y.-H.W.); (C.-T.Y.)
- Department of Medical Laboratory Science and Biotechnology, Yuanpei University of Medical Technology, Hsinchu City 30015, Taiwan
| | - Chia-Chang Wu
- Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan; (W.-L.W.); (O.A.B.); (S.-W.H.); (K.-Y.T.)
- TMU Research Center of Urology and Kidney (TMU-RCUK), Taipei Medical University, Taipei City 110, Taiwan
- Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 110, Taiwan
| |
Collapse
|
|
4
|
Zhang J, Zhang X, Cai Z, Li N, Li H. The Lifetime Risk and Prognosis of Chronic Prostatitis/Chronic Pelvic Pain Syndrome in the Middle-Aged Chinese Males. Am J Mens Health 2020; 13:1557988319865380. [PMID: 31311396 PMCID: PMC6637838 DOI: 10.1177/1557988319865380] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Knowledge is limited about the lifetime risk of chronic pelvic pain syndrome (CPPS) occurrence in Chinese middle-aged males and the prognosis of CPPS patients with and without treatment. Noninstitutionalized Chinese males aged 40 to 81 years were enrolled in this study from a total of 76 local communities across 30 provinces of China. Information about the occurrence of CPPS, symptom relief, and previous treatment was collected. Based on completed answers to specific questions about self-reported and physician-diagnosed CPPS, the lifetime risk of CPPS occurrence was 25.3% (1,091 out of 4,315) in Chinese males aged 40 to 81 years. Over 77% of patients with CPPS had received treatment. The symptom relief rate was not significantly different between the treatment (57.3%, 142/248) and nontreatment (50.1%, 422/843) groups. Regardless of whether patients had received medical treatment, engagement in sedentary work and regular alcohol consumption had a significant negative influence, while marriage had a positive influence, on the prognosis of CPPS. A good prognosis could be achieved without treatment for some cases of CPPS, while others required a timely symptom-orientated treatment using adequate medications combined with lifestyle adjustment and follow-up.
Collapse
Affiliation(s)
- Jianzhong Zhang
- 1 Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
| | - Xinyu Zhang
- 1 Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.,2 Department of Urology, Navy General Hospital of Chinese PLA, Beijing, China
| | - Zhonglin Cai
- 1 Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
| | - Ni Li
- 3 Program Office for Cancer Screening in Urban China, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, China
| | - Hongjun Li
- 1 Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
| |
Collapse
|
|
5
|
Di Vico T, Durante J, Polito C, Tognarelli A, Canale D, Caglieresi C, Morelli G, Bartoletti R. Pumpkin seeds, Centella asiatica, Boswellia, Helichrysum, acetate vitamin E, Melaleuca alternifolia and hyaluronic acid phytocomplex monotherapy effects in patients with chronic pelvic pain syndrome. MINERVA UROL NEFROL 2019; 72:236-242. [PMID: 31558010 DOI: 10.23736/s0393-2249.19.03450-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
BACKGROUND Proxelan® and antibiotics combined therapy was successfully previously used in the treatment of symptoms of patients with chronic prostatitis. Aim of the present study was to investigate the effects of Proxelan® monotherapy on pain symptoms of patients with chronic prostatitis (CP) or chronic pelvic pain syndrome (CPPS) in a prospective pilot study. METHODS Thirty consecutive patients with CP/CPPS symptoms younger than 50, without urinary obstruction, total prostate-specific antigen (PSA) <4 ng/mL, negative microbiology testing on prostate fluid and urethral swab, naïve from other treatments during the previous three months were enrolled in a pilot study. IPSS and NIH-CPSI questionnaires were administered to all the patients. Patients could choose to be investigated regarding semen quality and IL6/IL8 seminal markers for inflammatory disease prior and after the therapy course. Proxelan® suppositories were prescribed for each patient for a month with a daily dosage of 1 suppository at bed-time. The primary endpoint of the study included at least a 30% reduction of pain symptoms because similar results can be obtained in each previously investigated placebo group. Effects on semen parameters such as leukocytospermia, spermatozoa concentration and motility, cytokine levels were considered as secondary endpoints. RESULTS Subjective pain relief was obtained in all the patients with significant decrease of NIH-CPSI pain items (P=0.04). Urinary symptoms, investigated by IPSS questionnaire, decreased significantly (P=0.04) as well as quality of life items (P=0.04). Leukocytospermia was found in 5/15 patients available for further investigations. IL6 decreased by 11.55% one month after the treatment while sperm motility resulted increased by 17.3%. CONCLUSIONS Proxelan® monotherapy may represents a promising valid alternative to combined treatment with antibiotics in patients with CP/CPPS symptoms although the results obtained should be investigated in randomized controlled trials.
Collapse
Affiliation(s)
- Tommaso Di Vico
- Department of Translational Research and new Technologies, University of Pisa, Pisa, Italy -
| | - Jacopo Durante
- Department of Translational Research and new Technologies, University of Pisa, Pisa, Italy
| | - Chiara Polito
- Department of Translational Research and new Technologies, University of Pisa, Pisa, Italy
| | - Alessio Tognarelli
- Department of Translational Research and new Technologies, University of Pisa, Pisa, Italy
| | - Domenico Canale
- Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy
| | | | - Girolamo Morelli
- Department of Surgical, Medical and Molecular Pathology, University of Pisa, Pisa, Italy
| | - Riccardo Bartoletti
- Department of Translational Research and new Technologies, University of Pisa, Pisa, Italy
| |
Collapse
|
|
6
|
Farmer T, Johnston M, Milica A, Hindley R, Emara A. Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Literature Review of NIH III Prostatitis. CURRENT BLADDER DYSFUNCTION REPORTS 2019. [DOI: 10.1007/s11884-019-00508-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
|
7
|
McAchran SE. Common Causes, Diagnostic Evaluation, and Treatment in Men. Pain 2019. [DOI: 10.1007/978-3-319-99124-5_179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
|
8
|
Fusco A, Savio V, De Filippis A, Tufano A, Donnarumma G. Induction of Different Apoptosis Pathways by Two Proteus mirabilis Clinical Isolates Strains in Prostatic Epithelial Cells. Front Physiol 2018; 9:1855. [PMID: 30618851 PMCID: PMC6306403 DOI: 10.3389/fphys.2018.01855] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Accepted: 12/07/2018] [Indexed: 12/11/2022] Open
Abstract
Bacterial prostatitis is believed to be the leading cause of recurrent urinary tract infections (UTIs) in men under 50 years of age and occurs both as an acute febrile disease responsive to antibiotics and as a chronic infection that is often unresponsive to antibiotic treatment. Proteusmirabilis is more commonly associated with UTIs in these abnormalities, especially in patients undergoing catheterisation. This pathogen is able to colonise the host’s tissues and to cause disease thanks to the production of many virulence factors such as fimbriae, flagella, immune avoidance, host-damaging factors, and the ability to form crystalline biofilms. In addition, Proteus lipid A may exhibit apoptotic activity and induce desquamation of epithelial cells. The aim of this work was to evaluate the ability of two clinically isolated strains of P. mirabilis that are phenotypically different, named PM1 of PM2, respectively, to induce apoptosis in human prostatic adenocarcinoma PC-3. Our results demonstrate that PM1 and PM2 are able to activate two different apoptotic pathways, and this different behaviour is confirmed by the expression level of the ZapA gene, molecular fingerprinting and different spectrum of antibiotic resistance. The identification and knowledge of relations between the microorganism and host may provide the basis for new solutions to clinical problems with regard to diagnosis and therapy.
Collapse
Affiliation(s)
- Alessandra Fusco
- Department of Experimental Medicine, Section of Microbiology and Clinical Microbiology, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Vittoria Savio
- Department of Experimental Medicine, Section of Microbiology and Clinical Microbiology, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Anna De Filippis
- Department of Experimental Medicine, Section of Microbiology and Clinical Microbiology, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Antonio Tufano
- Urology School, Sapienza University of Rome, Rome, Italy
| | - Giovanna Donnarumma
- Department of Experimental Medicine, Section of Microbiology and Clinical Microbiology, University of Campania Luigi Vanvitelli, Naples, Italy
| |
Collapse
|